tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

SRPT Stock Latest News

Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty
Company AnnouncementsSarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty
4d ago
SRPT
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year
PremiumCompany Announcements
Sarepta Therapeutics Eyes 2026 Reset After Rocky Year
5d ago
SRPT
Sarepta price target lowered to $29 from $34 at Wedbush
PremiumThe Fly
Sarepta price target lowered to $29 from $34 at Wedbush
5d ago
SRPT
Sarepta price target lowered to $38 from $45 at Wells Fargo
PremiumThe Fly
Sarepta price target lowered to $38 from $45 at Wells Fargo
8d ago
SRPT
Sarepta price target lowered to $20 from $22 at Baird
PremiumThe Fly
Sarepta price target lowered to $20 from $22 at Baird
9d ago
SRPT
Sarepta downside risks outweigh upside potential, says Citi
PremiumThe FlySarepta downside risks outweigh upside potential, says Citi
9d ago
SRPT
Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta
Premium
Ratings
Cut Guidance, Clinical Uncertainty, and PMO Franchise Risk Underscore Negative Risk–Reward for Sarepta
9d ago
SRPT
Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside
Premium
Ratings
Maintaining Hold on Sarepta: Weaker Elevidys Outlook, Competitive PMO Pressures, and CEO Transition Temper Near‑Term Upside
9d ago
SRPT
Sarepta CEO to retire
PremiumThe Fly
Sarepta CEO to retire
10d ago
SRPT
Sarepta Therapeutics Announces Planned CEO Leadership Transition
PremiumCompany Announcements
Sarepta Therapeutics Announces Planned CEO Leadership Transition
10d ago
8K
SRPT
Sarepta reports Q4 adjusted EPS ($3.58), consensus (77c)
PremiumThe Fly
Sarepta reports Q4 adjusted EPS ($3.58), consensus (77c)
10d ago
SRPT
Sarepta announces commercial launch of Elevidys in Japan
PremiumThe Fly
Sarepta announces commercial launch of Elevidys in Japan
11d ago
CHRO
SRPT
SRPT Earnings this Week: How Will it Perform?
PremiumPre-EarningsSRPT Earnings this Week: How Will it Perform?
12d ago
SRPT
Court revives Regenxbio, UPenn patent suit against Sarepta, Bloomberg says
Premium
The Fly
Court revives Regenxbio, UPenn patent suit against Sarepta, Bloomberg says
15d ago
RGNX
SRPT
Sarepta receives approval to start SRP-1005 trial in New Zealand
Premium
The Fly
Sarepta receives approval to start SRP-1005 trial in New Zealand
1M ago
SRPT
Sarepta assumed with an Equal Weight at Barclays
PremiumThe Fly
Sarepta assumed with an Equal Weight at Barclays
1M ago
SRPT
Sarepta price target raised to $22 from $15 at Baird
PremiumThe Fly
Sarepta price target raised to $22 from $15 at Baird
1M ago
SRPT
Sarepta Therapeutics: Safety Uncertainty and Label Risk Overshadow Elevidys Data, Supporting Sell/High Risk Rating
PremiumRatings
Sarepta Therapeutics: Safety Uncertainty and Label Risk Overshadow Elevidys Data, Supporting Sell/High Risk Rating
1M ago
SRPT
H.C. Wainwright reiterates Sell on Sarepta after 3-year data
PremiumThe Fly
H.C. Wainwright reiterates Sell on Sarepta after 3-year data
1M ago
SRPT
Midday Fly By: Minnesota CEOs call for deescalation, Nvidia invests in CoreWeave
PremiumThe FlyMidday Fly By: Minnesota CEOs call for deescalation, Nvidia invests in CoreWeave
1M ago
LE
AMP
Sarepta rises 14.1%
Premium
The Fly
Sarepta rises 14.1%
1M ago
SRPT
Morning Movers: USA Rare Earth surges after government funding pact
Premium
The Fly
Morning Movers: USA Rare Earth surges after government funding pact
1M ago
AAUC
CRWV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >